Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial

Main Article Content

Stephan Weidinger
Department of Dermatology and Allergy, University Hospital Schleswig-Holstein, Kiel, Germany

Jonathan Silverberg
The George Washington University School of Medicine and Health Sciences, Washington, DC, USA

Darryl Toth
XLR8 Medical Research and Probity Medical Research, Windsor, ON, Canada

Thomas Bieber
Department of Dermatology and Allergy, University Medical Center, Bonn, Germany

Andrew Alexis
Icahn School of Medicine at Mount Sinai, New York, NY, USA

Boni Elewski
University of Alabama, Birmingham, AL, USA

Andrew Pink
St. John?s Institute of Dermatology, Guy?s and St. Thomas? Hospitals, London, UK

DirkJan Hignen
Department of Dermatology, Erasmus University Medical Center, Rotterdam, the Netherlands

Keywords

Atopic Dermatitis, Tralokinumab, Topical Cortocisteroid, Efficacy, Safety

Abstract

Abstract not available.

References

1. Weidinger S, Novak N. Lancet 2016; 387: 1109–1122.

2. Silverberg JI et al. Ann Allergy Asthma Immunol 2018; 121: 340–347.

3. Dalgard FJ et al. J Invest Dermatol 2015; 135: 984–991.

4. Bieber T. Allergy 2020; 75: 54–62.

5. Tsoi LC et al. J Invest Dermatol 2019; 139: 1480–1489.

6. Popovic B et al. J Mol Biol 2017; 429: 208–219.

7. Silverberg JI et al. Br J Dermatol 2020; in press.

Article Sidebar

Poster PDF
Published
Oct 27, 2020
DOI https://doi.org/10.25251/skin.4.supp.102

Article Details

How to Cite
[1]
Weidinger, S., Silverberg, J., Toth, D., Bieber, T., Alexis, A., Elewski, B., Pink, A. and Hignen, D. 2020. Efficacy and Safety of Tralokinumab Plus Concomitant Topical Corticosteroids (TCS) in Adult Patients with Moderate-to-Severe Atopic Dermatitis: Results from the 32-Week, Phase 3 ECZTRA 3 Trial. SKIN The Journal of Cutaneous Medicine. 4, 6 (Oct. 2020), s102. DOI:https://doi.org/10.25251/skin.4.supp.102.
Issue
Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Section
Atopic Dermatitis
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>